HRS2300 + SHR-1701

**HRS2300 + SHR-1701** is an experimental anticancer combination therapy under clinical investigation for advanced solid tumors. HRS2300 is a small molecule with an undefined mechanism, developed as an antineoplastic agent. SHR-1701 is a bifunctional fusion protein that combines a monoclonal antibody against programmed death-ligand 1 (PD-L1) with the extracellular domain of transforming growth factor beta receptor II (TGF-βRII), thus simultaneously inhibiting both the PD-L1 and TGF-β pathways. Dual blockade of these pathways is intended to enhance anti-tumor immune responses by overcoming tumor-induced immunosuppression. Clinical trials have been conducted in patients with various advanced malignancies to assess safety, tolerability, and preliminary antitumor activity, with SHR-1701 showing particular efficacy in subtypes such as gastric cancer. The combination including HRS2300 is being evaluated for possible synergistic or additive anti-tumor effects in advanced malignancies[1][2][3][4].